Sorafenib for the treatment of breast cancer

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

(2017) J. Baselga et al.   ANNALS OF ONCOLOGY

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial

(2016) Denise A. Yardley et al.   Clinical Breast Cancer

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

(2016) Sophia Frentzas et al.   NATURE MEDICINE

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

(2015) John R. Mackey et al.   JOURNAL OF CLINICAL ONCOLOGY

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

(2015) Claudia Allemani et al.   LANCET

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells

(2014) Turgut Kacan et al.   Asian Pacific Journal of Cancer Prevention

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

(2014) Sibylle Loibl et al.   Breast Care

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

(2014) L Bazzola et al.   BRITISH JOURNAL OF CANCER

Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer

(2014) Suleiman Massarweh et al.   Future Oncology

Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

(2014) Tina Kristensen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis

(2014) Jie Chen et al.   Journal of Breast Cancer

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

(2013) D. W. Miles et al.   ANNALS OF ONCOLOGY

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

(2013) Claudia Fumarola et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer

(2013) Thehang Luu et al.   Clinical Breast Cancer

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

(2013) L. S. Schwartzberg et al.   CLINICAL CANCER RESEARCH

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

(2013) Lida A. Mina et al.   INVESTIGATIONAL NEW DRUGS

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

(2013) John P. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

(2013) José Baselga et al.   Trials

1st International consensus guidelines for advanced breast cancer (ABC 1)

(2012) F. Cardoso et al.   BREAST

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

(2012) C. J. Peer et al.   CLINICAL CANCER RESEARCH

Target-based Anti-angiogenic Therapy in Breast Cancer

(2012) Markus Wehland et al.   CURRENT PHARMACEUTICAL DESIGN

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

(2012) William J. Gradishar et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

(2012) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

(2011) Nicholas J. Robert et al.   Clinical Breast Cancer

A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial

(2011) G. Mariani et al.   EUROPEAN JOURNAL OF CANCER

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

(2010) E. L. Mayer et al.   ANNALS OF ONCOLOGY

Synergistic activity of letrozole and sorafenib on breast cancer cells

(2010) Mara A. Bonelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

(2010) Claudine Isaacs et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(2010) Giorgio Valabrega et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

(2010) Maximilian Merz et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

(2010) J. S. Lagas et al.   MOLECULAR CANCER THERAPEUTICS

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

(2009) Giulia Bianchi et al.   ANTI-CANCER DRUGS

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer

(2009) John Mackey et al.   Clinical Breast Cancer

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

(2009) Fatima Cardoso et al.   JNCI-Journal of the National Cancer Institute

Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer

(2008) Q. Ding et al.   CANCER RESEARCH

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

(2008) Alvaro Moreno-Aspitia et al.   JOURNAL OF CLINICAL ONCOLOGY